Theriva Biologics, Inc.
TOVX · AMEX
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -161.40% | -155.39% | -198.84% | -249.96% |
| EV / EBITDA | 0.61 | 0.93 | 0.71 | 2.62 |
| Quality | ||||
| ROIC | -16.51% | -17.93% | -16.15% | -23.62% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.99 | 0.36 | 1.10 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.59% | -1.39% | -19.88% | -13.32% |
| Safety | ||||
| Net Debt / EBITDA | 0.83 | 1.62 | 0.93 | 2.93 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,023.33 | -1,512.69 | 937.99 | -2,061.82 |